NASDAQ:MRKR Marker Therapeutics (MRKR) Stock Price, News & Analysis $2.98 -0.15 (-4.79%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.77▼$3.2050-Day Range$2.95▼$5.9652-Week Range$2.40▼$6.80Volume41,995 shsAverage Volume27,556 shsMarket Capitalization$26.58 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Marker Therapeutics alerts: Email Address Marker Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside269.1% Upside$11.00 Price TargetShort InterestHealthy1.26% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.43) to ($1.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.81 out of 5 starsMedical Sector199th out of 910 stocksPharmaceutical Preparations Industry81st out of 426 stocks 3.5 Analyst's Opinion Consensus RatingMarker Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageMarker Therapeutics has received no research coverage in the past 90 days.Read more about Marker Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.26% of the float of Marker Therapeutics has been sold short.Short Interest Ratio / Days to CoverMarker Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marker Therapeutics has recently decreased by 17.75%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMarker Therapeutics does not currently pay a dividend.Dividend GrowthMarker Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMarker Therapeutics has received a 53.36% net impact score from Upright. Marker Therapeutics seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Marker Therapeutics is -0.75. Previous Next 1.4 News and Social Media Coverage News SentimentMarker Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marker Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.35% of the stock of Marker Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.39% of the stock of Marker Therapeutics is held by institutions.Read more about Marker Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Marker Therapeutics are expected to decrease in the coming year, from ($1.43) to ($1.46) per share.Price to Book Value per Share RatioMarker Therapeutics has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Marker Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About Marker Therapeutics Stock (NASDAQ:MRKR)Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.Read More MRKR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRKR Stock News HeadlinesAugust 20, 2024 | yahoo.comCheez-It factory site to receive Ohio Historical MarkerAugust 20, 2024 | yahoo.comOhio Historical Marker approved for Cheez-It factory site in DaytonSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 14, 2024 | globenewswire.comMarker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdatesAugust 12, 2024 | globenewswire.comMarker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's LymphomaAugust 10, 2024 | msn.comAishwarya Rai and the Zirak Marker factor: Is Abhishek Bachchan's marriage on the rocks?August 1, 2024 | msn.comHow Kate Marker found clarity with her fee structureJuly 29, 2024 | msn.comMan charged with intoxicated manslaughter after Howard County crashSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...July 25, 2024 | finance.yahoo.comITRCC to Begin Pavement Improvements on Indiana Toll Road From Mile Marker 10 to 20 in Lake County, INJuly 19, 2024 | finance.yahoo.comMarker Therapeutics (NASDAQ:MRKR) shareholders are up 20% this past week, but still in the red over the last five yearsJune 28, 2024 | investorplace.comMRKR Stock Earnings: Marker Therapeutics Reported Results for Q4 2023May 26, 2024 | msn.comSpecial bronze DAR 250 Patriots Marker to be dedicated Memorial Day at TPWM CenterMay 16, 2024 | msn.comCombining two tumor markers can help track down colorectal cancer subtypesMay 16, 2024 | investorplace.comMRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024May 15, 2024 | globenewswire.comMarker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 13, 2024 | msn.comReinstalling a Midstate MarkerMay 13, 2024 | msn.comFatal collision occurs on SH 176 at Mile Marker 240 in Andrews CountySee More Headlines Receive MRKR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRKR CUSIPN/A CIK1094038 Webwww.markertherapeutics.com Phone(713) 400-6400FaxN/AEmployees60Year Founded2018Price Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+269.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,240,000.00 Net Margins-278.27% Pretax Margin-276.47% Return on Equity-78.91% Return on Assets-66.10% Debt Debt-to-Equity RatioN/A Current Ratio5.92 Quick Ratio5.92 Sales & Book Value Annual Sales$3.31 million Price / Sales8.03 Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book2.73Miscellaneous Outstanding Shares8,920,000Free Float7,372,000Market Cap$26.58 million OptionableNot Optionable Beta1.55 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Juan F. Vera M.D. (Age 44)Co-Founder, CEO, President, Treasurer, Secretary & Director Comp: $399.25kMs. Elizabeth DonnellyDirector of AdministrationDr. Maria-Bernadette Madel (Age 34)Director of Corporate Operations & External Communications Mr. Edmund CheungVice President of Human ResourcesDr. Nadia Agopyan Ph.D.Senior Vice President of Regulatory AffairsDr. Monic Stuart M.D.Chief Medical OfficerPatricia AllisonHead of Clinical OperationsDr. Robert Z. Florkiewicz Sr.Senior Director of Molecular Biology & VirologyMore ExecutivesKey CompetitorsMetagenomiNASDAQ:MGXPyroGenesis CanadaNASDAQ:PYRGFAssertioNASDAQ:ASRTAnixa BiosciencesNASDAQ:ANIXCardiff OncologyNASDAQ:CRDFView All CompetitorsInstitutional OwnershipWedbush Securities Inc.Bought 24,000 shares on 8/7/2024Ownership: 0.779%View All Institutional Transactions MRKR Stock Analysis - Frequently Asked Questions How have MRKR shares performed this year? Marker Therapeutics' stock was trading at $5.50 at the beginning of 2024. Since then, MRKR stock has decreased by 45.8% and is now trading at $2.98. View the best growth stocks for 2024 here. How were Marker Therapeutics' earnings last quarter? Marker Therapeutics, Inc. (NASDAQ:MRKR) released its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.25) earnings per share (EPS) for the quarter. The company earned $1.17 million during the quarter. Marker Therapeutics had a negative net margin of 278.27% and a negative trailing twelve-month return on equity of 78.91%. Who are Marker Therapeutics' major shareholders? Top institutional investors of Marker Therapeutics include Wedbush Securities Inc. (0.78%). View institutional ownership trends. How do I buy shares of Marker Therapeutics? Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Marker Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA) and Strongbridge Biopharma (SBBP). This page (NASDAQ:MRKR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.